Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
AbbVie will pay the Danish antibody specialist Genmab $750 million as part of a deal to commercialize three of Genmab’s biospecific antibodies for cancer. Genmab could get another $3.2 billion in milestone payments. The pact joins Genmab antibodies, which can direct cytotoxic T cells to tumors, with AbbVie’s antibody-drug conjugate technology. Genmab already has threecommercialized antibodies under its belt through partnerships with Janssen, Novartis, and Roche.
This article has been sent to the following recipient: